Demant A/S DEMANT.CO
Composite 53/100; the shares have moved about 35% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 26/100 — a moderate mark against it.
Momentum ranks 80/100 — a strong point in its favour. Quality ranks 68/100 — a moderate point in its favour.
Growth ranks 26/100 — a moderate mark against it. Valuation ranks 43/100 — a slight mark against it. Balance-sheet strength ranks 44/100 — a slight mark against it.
What the company does Demant A/S is a Denmark-based hearing healthcare leader, designing and manufacturing hearing aids, operating clinics, and supplying diagnostic equipment to audiologists and ENT doctors globally.
Key financials Demant posts strong profitability with ROE 24.2%, ROA 6.9%, and ROCE 25.2%, supported by gross margins of 75.6% and operating margins of 18.1%. Revenue grew 3.4% but EPS fell 63.4%, reflecting higher costs and investments.
Stock health Momentum is robust with 3m +39.49% and 6m +21.26%, while RSI(14) at 64.30 signals mildly overbought conditions. Quality pillar scores 66.1 and momentum pillar 71.4 indicate resilient fundamentals and positive sentiment.
Price vs fair value The stock trades at a PREMIUM of 24.30% versus our fair-value estimate and a PREMIUM of 3.91% versus the 12-month analyst target. - Premium valuation vs fair-value estimate (24.30%) (Fair Value & Analyst View) - Premium vs consensus target (3.91%) (Fair Value & Analyst View) - High P/E 24.95 vs forward 21.60 and PEG 1.57 (Valuation) - Strong momentum pillar 71.4 despite modest revenue growth (Sideravia Score)
Looking forward Forward P/E of 21.60 and EV/EBITDA of 14.95 suggest the market is pricing in steady cash flows, while a dividend yield of n/a reflects reinvestment priorities. Analysts (n=20) see limited upside to the current price, implying a balanced risk/reward near term.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.